Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: A case-control study

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1341-1348

  De Mello, Ramon Andrade ^a,b   Ferreira, Mónica ^c,d   Costa, Sandra ^c,d   Costa, Bruno Marques ^c,d   Pires, Filipa Soares ^a   Neves, Inês ^a   Almeida, Maria Inês ^c,d   Cunha, João ^e   Oliveira, Pedro ^a   Hespanhol, Venceslau ^a   Reis, Rui Manuel ^c,d,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e HOSPITAL DE BRAGA   (Portugal)

^f Barretos Cancer Hospital   (Brazil)

Author keywords

Epidermal growth factor; Genetic polymorphism; Non small cell lung cancer; Risk assessment

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHROMOSOME 4; CONTROLLED STUDY; DNA ISOLATION; EPIDERMAL GROWTH FACTOR GENE; FALSE POSITIVE RESULT; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PORTUGAL; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 84868152951     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0382-7     Document Type: Article

References (42)

1. Araújo A, et al. Association between EGF +61A/G polymorphism and gastric cancer in Caucasians. World J Gastroenterol. 2011;17:488-92.
2. Araujo A, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancera review of the literature. Oncologist. 2007;12:201-10.
3. Bhowmick D, et al. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64:1220-3.
4. Cappuzzo F, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-9.
5. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216.
6. a edição proposta. Rev Port Pneumol. 2009;15:67-76.
7. Ciardiello F, Jezdic S. New insights on personalized cancer treatments: a report from the ESMO Congress. Expert Rev Anticancer Ther. 2011;11:21-3.
8. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-62.
9. Costa B, et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res. 2007;13:2621-6.
10. Costa B, et al. Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev. 2011;20:2610-7.
11. Dajczman E, et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol. 2008;3:1133-6.
12. De Mello RA, et al. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov. 2012;7:118-31.
13. De Mello RA, et al. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol. 2011;2:367-76.
14. Eberhard DA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-9.
15. Felip E, et al. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16:i28-9.
16. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-46.
17. Goto Y, et al. No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2454-6.
18. Harris R, et al. EGF receptor ligands. Exp Cell Res. 2003;284:2-13.
19. Herbst R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-9.
20. Hu-Lieskovan S, et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res. 2011;17:5161-9.
21. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
22. Kang H, et al. +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology. 2007;12:902-5.
23. Landi MT, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85:679-91.
24. Lee G, et al. XPC polymorphisms and lung cancer risk. Int J Cancer. 2005;115:807-13.
25. Li T, et al. Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol. 2012; doi: 10.1089/dna.2011.1394.
26. Lim Y, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett. 2005;374:157-60.
27. Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.
28. Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-8.
29. Mok T, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
30. Müllenbach R, et al. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 1989;5:391.
31. Sculier J, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3:457-66.
32. Shahbazi M, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359:397-401.
33. Shepherd F, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
34. Sholl L, et al. EGFR Mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133:922-34.
35. Takano T, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-37.
36. Tanabe K, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama. 2008;299:53-60.
37. Teixeira A, et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res. 2008;14:3367-71.
38. Wacholder S, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-42.
39. Wu G, et al. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg. 2009;33:124-9.
40. Zhang Y, et al. Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol. 2010;34:150-6.
41. Zhou C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancer Oncol. 2011;12:735-42.
42. Zhu C, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2008;26:4268-75.